DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for gout — screening already-approved drugs against its 41-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleGout maps to a 41-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for gout is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
interleukin 1 beta (IL1B) — IL1B is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5R8Q · 1.23 Å · ligand 1-methyl-N-{[(2S)-oxolan-2-yl]methyl}-1H-pyrazole-3-carboxamide (JGY). Experimental structure, not a prediction.
What the evidence adds up to
Gout is a painful inflammatory arthritis linked to hyperuricaemia and deposition of monosodium urate crystals. Diagnosed cases were estimated at 2.13% of the 2009 US population, with highest incidence in people aged 65 and older, and men more than twice as likely to be affected as women. Progression to chronic gout can result from poor compliance with, ineffectiveness of, or inability to tolerate urate-lowering therapies. Patients with high flare frequency, tophi, and inability to maintain serum urate below 6 mg/dL on therapy are categorised as having refractory chronic gout, and this small subgroup contributes disproportionately to the overall economic burden. Acute gout attacks often resolve spontaneously within 7–10 days, but the mechanism of this self-remission is not yet understood.
Approved urate-lowering drugs include allopurinol and febuxostat, and new recommendations have been presented on appropriate dosing of colchicine for acute flares and on potential toxicities when colchicine is combined with drugs such as clarithromycin. Emerging therapies in early and late phase trials include pegloticase, the uricosuric agent RDEA596, and the interleukin-1 inhibitors rilonacept and canakinumab. In extreme cases, surgical excision of tophi has been used, as in a reported 66-year-old male whose tophi in fingers and heel were excised after lifestyle changes and medical management failed to control his symptoms. Such surgery is now rare with the advent of uricosuric medication.
A 2024 Mendelian randomization study using data from FinnGen (7461 gout cases, 221,323 controls) identified 23 metabolites with potential genetic associations to gout. One metabolite, X-11529, was associated with increased gout risk (OR 1.225, 95% CI 1.112–1.350, P < 0.001). Others, such as piperine and stachydrine, appeared to confer protective effects. The analysis also suggested that 1-methylxanthine may be involved in gout through the caffeine metabolism pathway. These are genetic associations, not proven causal mechanisms.
Despite available treatments, management of gout remains suboptimal. What is still missing are large, well-designed trials that test whether the identified metabolite pathways can be targeted therapeutically, and patient stratification strategies to identify who will benefit from existing or emerging drugs rather than progressing to refractory disease.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Medical Research and Opinion · 2010 · 118 citations
Chronic gout: epidemiology, disease progression, treatment and disease burden
AbstractBACKGROUND: Gout is a painful and disabling inflammatory arthritis of increasing prevalence associated with hyperuricemia and the deposition of monosodium urate crystals in soft tissues and joints. Diagnosed gout cases have been estimated at 2.13% of the 2009 US population. The highest incidence occurs in the 65+ year age group, with males more than twice as likely to be afflicted as females. OBJECTIVE: To present the epidemiology of chronic gout and to discuss its disease burden. METHODS: This commentary is based on expert opinion and supplemented with published/presented information identified through PubMed and rheumatology associations. RESULTS: The steady rise of diagnosed gout cases can generally be linked to an aging population with multiple comorbidities, the use of certain prescription medications, and changes in diet and lifestyle. Progression to chronic gout has numerous causes such as poor compliance with, ineffectiveness of, or inability to tolerate prescribed regimens. Despite the availability of urate-lowering therapies (ULT), patients may either have contraindications to them or may not adequately respond. Patients with high flare frequency, tophi, and the inability to maintain serum urate levels below 6 mg/dL with ULT can be categorized as having chronic gout that is refractory, with a substantial disease burden. Based on lack of therapeutic options for urate-lowering for patients with chronic gout refractory to conventional therapy, the economic burden of this small but substantial population contributes disproportionately to the overall economic burden of chronic gout. Recent availability of gout-specific ICD-9-CM codes capturing the cost intense and impactful aspects of the disease - flares and tophi - is likely contribute to understanding the full health economic burden in gout. CONCLUSION: The impact of chronic gout, especially if refractory to treatment, on functionality, productivity, quality of life and health care costs can be substantial and is deserving of future research.
Current Opinion in Rheumatology · 2010 · 40 citations
Progress in the pharmacotherapy of gout
AbstractPURPOSE OF REVIEW: To summarize new knowledge on approved and emerging drugs used to treat hyperuricemia or the clinical manifestations of gout. RECENT FINDINGS: Results of several clinical trials provide new data on the efficacy and safety of the approved urate-lowering drugs, allopurinol and febuxostat. New recommendations have been presented on appropriate dosing of colchicine for acute gout flares and potential toxicities of combining colchicine with medications such as clarithromycin. Emerging therapies, including pegloticase, the uricosuric agent RDEA596, and the interleukin-1 inhibitors, rilonacept and canakinumab, have shown promise in early and late phase clinical trials. SUMMARY: Recent publications demonstrate an opportunity to use existing gout therapies more effectively in order to improve both efficacy and safety. Emerging therapies for gout show promise for unmet needs in selected gout populations.
Journal of International Medical Research · 1979 · 17 citations
Piroxicam in the Treatment of Acute Gout: A Multicentre Open Study in General Practice
AbstractTwenty-nine patients with acute gout were treated with piroxicam (40 mg daily for 5 days) in a multicentre general practitioner study. Pain relief was noticeable within 4 hours of the first dose and thereafter proceeded steadily, together with the early relief of other symptoms associated with acute gout. The prompt relief of symptoms was accompanied by a fall in serum uric acid. Piroxicam was well tolerated, eight experiencing side-effects that were mainly mild and gastro-intestinal in nature. The drug seems to be highly effective and safe in the treatment of acute gout.
Spontaneous resolution of acute gout: mechanisms and therapeutic targets
AbstractGout is a common inflammatory arthritis that has been increasing in both prevalence and incidence. Consequently, management of refractory and chronic gout has been gaining attention. Onset of gout is related to the deposition of monosodium urate crystals under hyperuricaemia. Interestingly, acute gout attacks often resolve spontaneously within 7-10 days, and many studies have confirmed the notion that gout flares can be self-relieved. However, the underlying mechanism for spontaneous remission of gout requires further elucidation. In this article, we summarise the roles and mechanisms related to spontaneous remission of gout, which are essential for understanding its pathogenesis and developing potential targeted therapies.
A Case of Surgically Intervened Chronic Tophaceous Gout and Review of Literature.
AbstractBACKGROUND: Gout is a disease of deposition of monosodium urate crystal in the body which commonly presents as an acute arthritis of the peripheral joints but can have varied presentation. It is mostly managed by dietary modifications and drugs, but surgery is rarely required for the management of urate crystals. CASE REPORT: We present a case of a 66-year-old male who intermittently presented to the outpatient with multiple tophi which was managed with lifestyle changes and medically; initially, the patient eventually required surgical excision for tophi in fingers and heel which improved the pain and morbidity of the patient. CONCLUSION: Gout can be managed by lifestyle changes, medically by drugs, and in extreme cases surgically and requires the utmost compliance by the patient. Such surgical intervention is rare with the advent of uricosuric medication now.
Swiss Medical Weekly · 2016 · 2 citations · open access
Guidelines for the treatment of gout: a Swiss perspective
AbstractGout is a common condition and its management is suboptimal. A number of guidelines on the management of gout have been published in the last decade by professional societies with the aim of informing the physician of the recommended therapeutic strategies and the treatment options. We have tried to synthesize the current recommendations and to highlight some challenges that still need to be resolved in clinical practice in Switzerland.
European Journal of Clinical Nutrition · 2024 · 2 citations · open access
Specific blood metabolite associations with Gout: a Mendelian randomization study
AbstractOBJECTIVE: Gout, common metabolic disorders, have poorly understood links with blood metabolites. Exploring these relationships could enhance clinical prevention and treatment strategies. METHODS: We applied bidirectional two-sample Mendelian randomization (MR) analysis, using data from a genome-wide association (GWAS) study of 486 blood metabolites. Gout data was obtained from FinnGen R8 (7461 gout and 221,323 control cases). We implemented the inverse variance-weighted (IVW) method for main analytical approach. Extensive heterogeneity, pleiotropy tests, leave-one-out analysis, and reverse MR were conducted to validate the robustness of our findings. Both Bonferroni and False Discovery Rate (FDR) corrections were used to adjust for multiple comparisons, ensuring stringent validation of our results. RESULTS: Initial MR identified 31 candidate metabolites with potential genetic associations to gout. Following rigorous sensitivity analysis, 23 metabolites as potential statistical significance after final confirmation. These included metabolites enhancing gout risk such as X-11529 (OR = 1.225, 95% CI 1.112-1.350, P < 0.001), as well as others like piperine and stachydrine, which appeared to confer protective effects. The analysis was strengthened by reverse MR analysis. Additionally, an enrichment analysis was conducted, suggesting that 1-methylxanthine may be involved in the metabolic process of gout through the caffeine metabolism pathway. CONCLUSION: Identifying causal metabolites offers new insights into the mechanisms influencing gout, suggesting pathways for future research and potential therapeutic targets.
AbstractThe purpose of this book is to provide an update on the epidemiology, pathophysiology, clinical symptoms, treatment, management, and ongoing research in gout. Accepted submissions are of high scientific value based on previous research and include novel and innovative research. This book is a valuable resource for physical clinicians who have the opportunity to treat gout. The scientific content of this book will be beneficial to patients, students, researchers, educators, and healthcare providers who are interested in the recent progress in gout research and therapy, not only physical clinicians.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
